OpenURL Connection Search

Select item for more details and to access through your institution.

Results of a UK National Cancer Research Institute Phase II study of brentuximab vedotin using a response‐adapted design in the first‐line treatment of patients with classical Hodgkin lymphoma unsuitable for chemotherapy due to age, frailty or comorbidity (BREVITY)
Published in:
British Journal of Haematology, 2021, v. 193, n. 1, p. 63, doi. 10.1111/bjh.17073
By:
- Gibb, Adam;
- Pirrie, Sarah J.;
- Linton, Kim;
- Warbey, Victoria;
- Paterson, Kathryn;
- Davies, Andrew J.;
- Collins, Graham P.;
- Menne, Tobias;
- McKay, Pamela;
- Fields, Paul A.;
- Miall, Fiona M.;
- Nagy, Eszter;
- Wheatley, Keith;
- Reed, Rachel;
- Baricevic‐Jones, Ivona;
- Barrington, Sally;
- Radford, John
Publication type:
Article
Bendamustine can be a bridge to allogeneic transplantation in relapsed Hodgkin lymphoma refractory to brentuximab vedotin.
Published in:
British Journal of Haematology, 2017, v. 179, n. 5, p. 841, doi. 10.1111/bjh.14257
By:
- Howell, Matthew;
- Gibb, Adam;
- Radford, John;
- Linton, Kim
Publication type:
Article
Results of a multicentre UK-wide retrospective study evaluating the efficacy of brentuximab vedotin in relapsed, refractory classical Hodgkin lymphoma in the transplant naive setting.
Published in:
British Journal of Haematology, 2017, v. 179, n. 3, p. 471, doi. 10.1111/bjh.14898
By:
- Eyre, Toby A.;
- Phillips, Elizabeth H.;
- Linton, Kim M.;
- Arumainathan, Arvind;
- Kassam, Shireen;
- Gibb, Adam;
- Allibone, Suzanne;
- Radford, John;
- Peggs, Karl;
- Burton, Cathy;
- Stewart, Gillian;
- LeDieu, Rifca;
- Booth, Catherine;
- Osborne, Wendy L.;
- Miall, Fiona;
- Eyre, David W.;
- Ardeshna, Kirit M.;
- Collins, Graham P.
Publication type:
Article
Profile of brentuximab vedotin and its potential in the treatment of relapsed or refractory Hodgkin lymphoma.
Published in:
Blood & Lymphatic Cancer: Targets & Therapy, 2012, v. 2, p. 99, doi. 10.2147/BLCTT.S21989
By:
- Mayes, Sam;
- Gibb, Adam;
- Illidge, Tim
Publication type:
Article

Found: 4

Results of a UK National Cancer Research Institute Phase II study of brentuximab vedotin using a response‐adapted design in the first‐line treatment of patients with classical Hodgkin lymphoma unsuitable for chemotherapy due to age, frailty or comorbidity (BREVITY)

Bendamustine can be a bridge to allogeneic transplantation in relapsed Hodgkin lymphoma refractory to brentuximab vedotin.

Results of a multicentre UK-wide retrospective study evaluating the efficacy of brentuximab vedotin in relapsed, refractory classical Hodgkin lymphoma in the transplant naive setting.

Profile of brentuximab vedotin and its potential in the treatment of relapsed or refractory Hodgkin lymphoma.